Conditions: Chronic Lymphocytic Leukemia Indolent Non-Hodgkin Lymphoma Follicular Lymphoma Small Lymphocytic Lymphoma Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia) Marginal Zone Lymphoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 6
Healthy volunteers: no

Brief summary:
The primary objective of this study is to evaluate the 28-day safety and tolerability, and to determine the pharmacokinetics (PK) of idelalisib in Japanese participants with relapsed or refractory indolent B-cell non-Hodgkin lymphomas (iNHL) or chronic lymphocytic leukemia (CLL).

Detailed description:

Arms:
arm 1: Participants with iNHL or CLL will receive idelalisib until the earliest of the following: unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anticancer or experimental therapy, investigator discretion, or idelalisib discontinuation.

Interventions: intervention 1: Idelalisib
Intervention descriptions: intervention 1: 150 mg tablet(s) administered orally twice daily

Protocol document: